ID   P3XBcl-2-13
AC   CVCL_B6NI
DR   Wikidata; Q112129483
RX   PubMed=9309429;
CC   Group: Hybridoma fusion partner cell line.
CC   Characteristics: Enhances the outgrowth of hybridomas following somatic fusion with immune lymphocytes isolated from pooled peripheral lymph nodes (PLN) 8-14 days after the initial immunization (PubMed=9309429).
CC   Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine.
CC   Transfected with: HGNC; 990; BCL2.
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Breed/subspecies: BALB/c.
DI   NCIt; C125417; Mouse plasma cell myeloma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_4032 ! P3X63Ag8.653
SX   Female
CA   Cancer cell line
DT   Created: 17-03-22; Last updated: 21-03-23; Version: 3
//
RX   PubMed=9309429; DOI=10.1089/hyb.1997.16.381;
RA   Kilpatrick K.E., Wring S.A., Walker D.H., Macklin M.D., Payne J.A.,
RA   Su J.-L., Champion B.R., Caterson B., McIntyre G.D.;
RT   "Rapid development of affinity matured monoclonal antibodies using
RT   RIMMS.";
RL   Hybridoma 16:381-389(1997).
//